0
0.5
1
1.5
2+
Mortality
-282%
Improvement
Relative Risk
Mortality (b)
-217%
Mortality (c)
-317%
Mortality (d)
-311%
Recovery
1%
Recovery (b)
12%
Recovery (c)
-1%
Recovery time
0%
no CI
Recovery time (b)
0%
no CI
Recovery time (c)
0%
no CI
Viral clearance
12%
Viral clearance (b)
-2%
Viral clearance (c)
21%
Viral clearance (d)
8%
Viral clearance (e)
-48%
Viral clearance (f)
21%
Molnupiravir MOVe-IN LATE TREATMENT DB RCT
Is late treatment with molnupiravir beneficial for COVID-19?
Double-blind RCT 291 patients in multiple countries (Oct 2020 - Jan 2021)
Higher mortality (p=0.31) and improved viral clearance (p=0.57), not sig.
c19early.org
Arribas et al., NEJM Evidence, December 2021
Favors molnupiravir
Favors control